Bilici, A. Et Al. 2023. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.. Acta oncologica (Stockholm, Sweden) , 1-10.

Bilici, A., Olmez, O. F., Kaplan, M. A., Oksuzoglu, B., Sezer, A., Karadurmus, N., ... Cubukcu, E.(2023). Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.. Acta oncologica (Stockholm, Sweden) , 1-10.

Bilici, Ahmet Et Al. "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.," Acta oncologica (Stockholm, Sweden) , 1-10, 2023

Bilici, Ahmet Et Al. "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.." Acta oncologica (Stockholm, Sweden) , pp.1-10, 2023

Bilici, A. Et Al. (2023) . "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.." Acta oncologica (Stockholm, Sweden) , pp.1-10.

@article{article, author={Ahmet Bilici Et Al. }, title={Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.}, journal={Acta oncologica (Stockholm, Sweden)}, year=2023, pages={1-10} }